WELCOME

PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar has five novel compounds: Yondelis® has received Authorization for Commercialization from the European Commission for advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Yondelis® is also in phase III for ovarian cancer and phase II for prostate, breast and paediatric cancers. Aplidin®, Kahalalide F, Zalypsis® and PM02734 are in clinical trials. PharmaMar also has a rich pipeline of preclinical candidates, and a strong R&D programme.